From plant extract to molecular panacea: A commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1666, 2015, Pages

  Wood, John N ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Seoul National University   (South Korea)

Author keywords

Aspirin; Cardiovascular function; Fever; Inflammation; Malaria; Pain

Indexed keywords

DISEASE TREATMENT; DRUG; EIGHTEENTH CENTURY; HEALTH CARE; MOLECULAR ANALYSIS; WOOD;

SALIX;

ANTIINFLAMMATORY AGENT; PLANT EXTRACT;

BARK; CHEMISTRY; HISTORY; PHARMACOLOGY; WILLOW;

ANTI-INFLAMMATORY AGENTS; HISTORY, 18TH CENTURY; PHARMACOLOGY; PLANT BARK; PLANT EXTRACTS; SALIX;

EID: 84924326183     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0317     Document Type: Review

References (28)

1. Stone E. 1763 An account of the success of the bark of the willow in the cure of agues. Phil. Trans. 53, 195-200. (doi:10.1098/rstl.1763.0033).
2. Jeffreys D. 2005 Aspirin: the remarkable story of a wonder drug. New York, NY: Bloomsbury..
3. Lévesque H, Lafont O. 2000 Aspirin throughout the ages: a historical review. Rev. Med. Interne 21(Suppl. 1), 8s-17s. (doi:10.1016/S0248- 8663(00)88720-2).
4. Pierpoint WS. 1997 Edward Stone (1702-1768) and Edmund Stone (1700-1768): confused identities resolved. Notes Rec. R Soc. Lond. 51, 211-217. (doi:10.1098/rsnr.1997.0018).
5. Dobson MJ. 1994 Malaria in England: a geographical and historical perspective. Parassitologia 36, 35-60..
6. Herbermann C (ed.) 1913 Jesuit's bark. Catholic encyclopedia. NewYork, NY: Robert Appleton Company..
7. Turkington C. 2007 The encylopedia of infectious diseases. New York, NY: Infobase..
8. Mossiker F. 1983 Madame de Sévigné: a life and letters. New York, NY: Knopf..
9. Laughton JK. Ringrose, Basil. In Dictionary of national biography, 1885-1900, vol. 48. London, UK: Smith, Elder & Co..
10. Cook HJ. 2011 Markets and cultures: medical specifics and the reconfiguration of the body in early modern Europe. Trans. R. Hist. Soc. (Sixth Series) 21, 123-145. (doi:10.1017/S008044 0111000065).
11. Wallis P. 2012 Exotic drugs and English medicine: England's drug trade, c.1550-c.1800. Soc. Hist. Med. 25, 20-46. (doi:10.1093/shm/hkr055).
12. Wilson A. 1990 The politics of medical improvement in early Hanoverian London. In The medical enlightenment of the eighteenth century (eds A Cunningham, HR French), pp. 4-39. Cambridge, UK: Cambridge University Press.
13. Maehle A-H. 1999 Drugs on trial: experimental pharmacology and therapeutic innovation in the eighteenth century. Amsterdam, The Netherlands: Rodopi..
14. Shulaev V, Silverman P, Raskin I. 1997 Airborne signalling by methyl salicylate in plant pathogen resistance. Nature 385, 718-721. (doi:10.1038/ 385718a0).
15. Zhu F, Xi DH, Yuan S, Xu F, Zhang DW, Lin HH. 2014 Salicylic acid and jasmonic acid are essential for systemic resistance against tobacco mosaic virus in Nicotiana benthamiana. Mol. Plant Microbe Interact 27, 567-577. (doi:10.1094/MPMI-11-13- 0349-R).
16. Buchner A. 1828 Ueber das Rigatellische Fiebermittel und über eine in der Weidenrinde entdeckte alcaloidische Substanz. Repertorium für die Pharmacie 29, 405-420..
17. Gerhardt C. 1853 Recherches sur les acides organiques anhydrides (Research on organic acid anhydrides). Ann. Chim. Phys. 37, 285-342..
18. Schröder A, Prinzhorn A, Kraut K. 1869 Uber Salicylverbindungen. Ann. Chem. Pharm. 150, 1-20. (doi:10.1002/jlac.18691500102).
19. Sneader W. 2000 The discovery of aspirin: a reappraisal. BMJ 321, 1591-1594. (doi:10.1136/ bmj.321.7276.1591).
20. Ferreira SH, Moncada S, Vane JR. 1971 Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New Biol. 231, 237-239. (doi:10.1038/newbio231237a0).
21. Harman CA, Turman MV, Kozak KR, Marnett LJ, Smith WL, Garavito RM. 2007 Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J. Biol. Chem. 282, 28 096-28 105. (doi:10.1074/ jbc.M701335200)..
22. Moncada S. 2004 Adventures in pharmacology, aspirin, prostacyclin and nitric oxide. Acta Cardiol. 59(Suppl. 1), 47-50..
23. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. 1992 Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23, 1400-1403. (doi:10.1161/01.STR.23.10.1400).
24. Kurumbail RG et al. 1996 Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 384, 644-648. (doi:10.1038/384644a0).
25. Mukherjee DM, Nissen SE, Topol EJ. 2001 Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 186, 954-959. (doi:10.1001/jama.286. 8.954).
26. Topol EJ. 2004 Failing the public health- Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351, 1707-1709. (doi:10.1056/NEJMp048286).
27. Algra AM, Rothwell PM. 2012 Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527. (doi:10.1016/S1470- 2045(12)70112-2).
28. Alfonso L, Ai G, Spitale RC, Bhat GJ. 2014 Molecular targets of aspirin and cancer prevention. Br. J. Cancer 111, 61-67. (doi:10.1038/bjc. 2014.271).